WILLIAN is set to depart Chelsea this summer with contract talks between the Brazilian and the Blues reportedly dead in the water.The Brazilian has been tipped to make a high-profile switch across London to join either Arsenal or Tottenham when his deal expires at the end of June.2 Willian is set to leave Chelsea on a free transfer this summerCredit: PA:Press AssociationThe 31-year-old has admitted he wants to remain at Stamford Bridge but negotiations have reached an impasse with the winger demanding a third season added to the club’s two-year offer.Willian is also thought to be seeking a pay rise which Chelsea are unable to match due to their previous policy concerning extensions to players over 30.CHELSEA NEWS LIVE: Follow for the latest Blues newsAs a result, Football London report that talks between the two are now dead in the water.It’s claimed Willian has no issue ditching Chelsea for a London rival if there is no sudden breakthrough in the next few months.He has made no secret of his desire to remain in the capital, where he has lived with his family for the last seven years.Arsenal were said to be leading the way at the end of April but Tottenham have been given an edge by Willian’s close relationship with former manager Jose Mourinho.Despite admitting that he is still on good terms with his ex Chelsea boss, the player’s entourage have denied reports that contact with Spurs has been made.Meanwhile, Willian’s agent Kia Joorabchian has become an increasingly influential figure at Arsenal over the past year.2Most Read in FootballTHROUGH ITRobbie Keane reveals Claudine’s father was ’50-50′ in coronavirus battleTOP SELLERGavin Whelan has gone from League of Ireland to David Beckham’s InstagramI SAW ROORodallega saw Rooney ‘drinking like madman’ & Gerrard ‘on bar dancing shirtless’PicturedAN EYEFULMeet Playboy model and football agent Anamaria Prodan bidding to buy her own clubExclusiveRIYAD RAIDMan City’s Riyad Mahrez has three luxury watches stolen in £500,000 raidNEXT STEPJonny Hayes set to move to English Championship having been let go by CelticThe 48-year-old pulled the strings on deals to bring David Luiz and loanee Cedric Soares to the Emirates.But if Willian is seen to be dragging his heels, that will not impress Gunners boss Mikel Arteta who has warned that he is not interested in players who hesitate over joining his club.The Brazil international has confirmed that should the season be extended beyond his contract he will stay and see out the campaign because of his “loyalty” to Chelsea.Chelsea forward Willian agrees to Tottenham transfer with reps having already discussed move with José Mourinho, says Richard Keys
Source:http://www.abbvie.com/ Jun 25 2018AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.This collaboration broadens AbbVie’s oncology research to access advanced precision medicine technology to expand the development of potentially life-changing treatments for patients with cancer.Chimeric Antigen Receptor T-cell (CAR-T) therapies harness the power of a cancer patient’s own immune system to attack and destroy cancer cells. Despite promising results in hematological malignancies, current CAR-T therapies in development for solid tumors have demonstrated limitations due to rapid activation and expansion of CAR-T cells that can lead to serious adverse events. Calibr’s novel cell therapy program, led by Travis Young, PhD, director of protein sciences at Calibr, is designed to enhance safety, versatility and efficacy through a proprietary modular “switchable” CAR-T cell that uses antibody-based switch molecules to control the activation and antigen specificity of CAR-T cells. Calibr’s proprietary technology may enable the development of universal CAR-T-based treatments across several types of hematological and solid tumor indications.”Calibr has assembled a premier scientific team and developed an innovative cell therapy technology that can take us to the next frontier of cancer treatment,” says Mohit Trikha, PhD, vice president and head of Oncology Early Development at AbbVie. “The combination of AbbVie’s oncology discovery and early development expertise and Calibr’s novel switchable CAR-T therapy platform aims to advance the current standard of care, with the potential rapidly advancing new treatment options for patients.”Related StoriesNanoparticles used to deliver CRISPR gene editing tools into the cellComprehensive cell atlas of the human liverExciting study shows how centrioles center the process of cell division”We’re delighted to work together with a strong partner like AbbVie to expand the impact of the CAR-T cell field to a broader range of cancers,” says Peter Schultz, PhD, chief executive officer of Calibr and Scripps Research.Under the terms of the license agreement, AbbVie will pay Calibr an upfront license fee and gain exclusive access to Calibr’s switchable CAR-T platform for a term of up to four years. The two organizations will work together to develop T-cell therapies directed to solid tumor targets identified by AbbVie. AbbVie also has the option to develop additional cell therapies toward AbbVie-nominated targets and license existing Calibr cell therapy programs under development for hematological and solid cancers, including Calibr’s lead program. Calibr plans to enter this lead candidate into clinical studies for lymphoma in 2019. In addition, the agreement provides AbbVie with an option to acquire an exclusive license to Calibr’s switchable CAR-T platform and programs within the first four years of the collaboration. The companies will share responsibility for preclinical development, with AbbVie responsible for clinical development and commercialization, and Calibr eligible to receive success-based milestone payments and royalties. The transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.